'Strikingly Positive' Effect of Novel MS Agent

Phase 2 data on the investigational drug frexalimab show favorable safety and significant reduction in new T1 brain lesions in relapsing MS.
Medscape Medical News

source https://www.medscape.com/viewarticle/993011?src=rss